We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Deal with Absci is the latest between big pharma and tech companies to build new disease treatments
Steady shift towards outsourcing hip, knee and eye treatment expected to expand to other procedures despite concerns
Group plans to refocus on 30 core brands
Decision is setback for US drugmaker looking to increase sales after pandemic
Any combination would likely encounter tough antitrust scrutiny
Expect earnings estimates to weaken following the FDA’s safety communication
Key drugs are due to lose exclusivity in the important US market in 2027
Clampdown on visas will not solve workforce crisis in underfunded sector, say unions and employers
Cancer Research UK report says UK government must invest in staffing and funding for research
Innovative models can drive funding for research on neglected, less survivable diseases
Danish pharma group in talks with healthcare providers about innovative models to boost Wegovy take-up
Demand is soaring thanks to the NHS crisis, but providers are up against inflation and fierce competition for doctors
Bill Anderson says group is generating a series of promising new drugs after R&D strategy change
Health body’s concern reflects heightened vigilance over signs of disease outbreaks since Covid pandemic
Halted trial of prospective blockbuster treatment follows latest US legal blow over weedkiller Roundup
Health leaders have called for urgent cash injection after wave of strikes
Vaccine recipient claims he suffered side effect of severe blood clot
Rooting out manipulation should not depend on dedicated amateurs who take personal legal risks for the greater good
How pension funds’ investments have impacted the London Stock Exchange
Claimants previously assessed as too sick for a job worried they could be told to work from home
Growth cap on UK’s health service branded drugs bill will rise to 4% from 2027
German group says prospective blockbuster asundexian failed to demonstrate efficacy
Also in this newsletter: Why tourists and residents are fighting over Rome’s sidewalks
A new crop of weight-loss drugs is disrupting markets as well as transforming waistlines
Royal College of GPs urges government to take action over ‘unsafe’ infrastructure ahead of Autumn Statement
International Edition
